Back

Candida dubliniensis in a general hospital over an 8-year period

Abstract number: 1733_776

Guembe M., Peláez T., Matesanz C., Torres-Narbona M., Guinea J., Alcalá L., Bouza E., Muñoz P.

Objectives:C. dubliniensis is a recognized fungal pathogen causing mucosal disease in AIDS patients. We investigated the incidence and antifungal susceptibility of C. dubliniensis isolated from clinical samples during an 8-year period in our hospital (1999–2006).

Methods: The antifungal susceptibility patterns for amphotericin B (AB), fluconazole (FZ), itraconazole (IZ), ketoconazole (KZ), voriconazole (VZ), posaconazole (PZ), flucytosine (FC), and caspofungin (CS) were determined by the broth microdilution method (Sensititre YeastOne YO7) and E test. The isolates were identified as C. dubliniensis by their inability to grow at 45°C and by rapID 32 C (bioMérieux).

Results: A total of 76 isolates of C. dubliniensis (49 patients) were recorded. The distribution of isolates and patients (isolates/patients) during the study period was as follows: 1999 (1/1), 2000 (0/0), 2001 (4/4), 2002 (11/5), 2003 (6/6), 2004 (30/23), 2005 (6/2) and 2006 (18/8). Clinical isolates were obtained from mucocutaneous sites (17/22%), respiratory tract samples (51/67%) and normally-sterile sites (8/11%). Overall, 35 of our 49 patients were HIV-infected. The MIC ranges (mg/L) of antifungal agents tested against C. dubliniensis were as follows: AB (0.008–0.06), FZ (0.06–1), IZ (0.008–0.125), KZ (0.008–0.03), VZ (0.008–0.016), PZ (0.002–0.25), FC (0.003–0.5), and CS (0.016–0.5). The overall geometric mean and MIC90 (mg/L) were as follows: AB (0.034/0.06), FZ (0.117/0.25), IZ (0.020/0.06), KZ (0.010/0.016), VZ (0.008/0.008), PZ (0.018/0.125), FC (0.043/0.006), and CS (0.096/0.25.

Conclusions:C. dubliniensis is increasingly isolated in our microbiology laboratory and remains susceptible ``in vitro'' to the most commonly used antifungal agents.

Session Details

Date: 31/03/2007
Time: 00:00-00:00
Session name: European Society of Clinical Microbiology and Infectious Diseases
Subject:
Location: ICC, Munich, Germany
Presentation type:
Back to top